Annual Report 2017
Vitrolife has today published its Annual Report for 2017. The document is attached to this press release and is also available on www.vitrolife.com.
Distribution of the printed versions of the annual reports to those shareholders who have requested dispatch, will be done by mail during the week commencing 9 April.
The printed version of the Annual Reports can be ordered on the company's website www.vitrolife.com, by phone +46 (0)31 721 80 00 or by email firstname.lastname@example.org.
28 March 2018
VITROLIFE AB (publ)
Queries should be addressed to:
Mikael Engblom, CFO, tel 46 31 721 80 14
This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on March 28, 2018.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.
Vitrolife has approximately 370 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: email@example.com. Website: www.vitrolife.com/